[Neoplasms during the 1st year of life: a study of 116 cases treated during the last 10 years]. / Neoplasias en el primer año de la vida: estudio de 116 casos tratados en los ultimos diez años.

116 infants under one year of age (14 per 100) with malignancies including 35 neuroblastomas, 23 retinoblastomas, 14 Wilm's tumours, 10 hepatoblastomas, 10 brain tumours, 9 germ cell tumours, 8 histiocytic and 7 soft tissue sarcomas, were treated in the last ten years. Hepatoblastoma is the highest relative incidence tumor in the first year of life and with brain tumours has the worst prognosis (50 and 40 per 100, respectively). The disease-free survival rate is most than 80 per 100 in neuro and nephroblastoma with medical and surgical treatment. Familiar incidence in Wilm's tumor is 42 per 100 and chemotherapy side effects are 23 per 100. Familiar incidence in neuroblastoma is 20 per 100 and chemotherapy side effects 21 per 100. In conclusion, in children with malignancies under one year of age have good prognosis (75 per 100 survival at five years), with lower surgical complications rate. Early diagnosis and response to chemotherapy, the side effects of which are considerable and should be strictly controlled, are key factors in the better prognosis and increased life expectancy in this group of patients.

[Six-month treatment of pulmonary tuberculosis in children. Review of 11 cases]. / Tratamiento de seis meses en tuberculosis pulmonar infantil. Revisión de 11 casos.

Between April 1987 and April 1988, 11 children with the diagnosis of pulmonary tuberculosis, have been treated with a short-course chemotherapy consisting in the administration of isoniacid (10-20 mg/kg, maximum 300 mg), rifampicin (10-20 mg/kg, maximum 600 mg), ethambutol (15-25 mg/kg, maximum 2.5 g) and pyraxinamide (15-30 mg/kg, maximum 2g) daily for two months, followed by the administration of isoniacid and rifampicin at the same dosage, daily, for the next four months. The results were excellent, symptoms cleared in few days and laboratory values and radiographic alterations cleared in few weeks. Only one of the children had to discontinue the therapy for a pyrazinamide intoleration. The advantages of this treatment are evident, short-course suppose greater comfort for the patient, a better observance of the therapy and less cost with a similar efficacy and without a larger incidence of adverse effects. We conclude that this therapy could be in children so useful than in adults, although more studies with larger series are needed.